UK approves J&J's daily pill for plaque psoriasis

Britain's medicines regulator MHRA has approved Johnson & Johnson's oral drug Icotyde for adults and teenagers aged 12 and above, weighing at least 40 kg, with moderate-to-severe plaque psoriasis. The decision rests on four late-stage trials involving 2,500 people, where patients did better after 16 weeks than those on placebo. The US approved it earlier this year.